| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 35.92 | 0.00 (0.00%) | 28.62 - 37.78 | 11.0 (Below Avg) |
Market data as of 4:01PM 05/21/13. Quotes are delayed by at least 15 min.
| Open | -- |
|---|---|
| Previous Close | 35.92 |
| Day's Range | -- - -- |
| Market Cap | 5.9B |
| Avg Volume (10 Day) | 1.4M |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.43 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Fail |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Hospira Reappoints Dr. Sumant Ramachandra Chief Scientific Officer
PR Newswire - Tuesday 05/14/2013 9:00 AM ET
Hospira Convenes Its 2013 Annual Meeting of Shareholders
PR Newswire - Wednesday 05/08/2013 12:55 PM ET
Hospira Reports First-Quarter 2013 Results
PR Newswire - Wednesday 05/01/2013 7:30 AM ET
Hospira Unveils Global Device Strategy
PR Newswire - Wednesday 05/01/2013 7:21 AM ET
Hospira Marks Five Years of Biosimilars Success at 2013 BIO International Convention
Business Wire - Wednesday 04/24/2013 10:36 AM ET
| HSP | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -0.26% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.59 | |
| LT Debt/Equity | 0.57 | |
| Earnings Yield | -- | |
| Price/Sales | 1.48 |
| Company | Last | Change |
|---|---|---|
| Elan Corporation PLC | 12.07 | 0.00% |
| Alkermes Plc | 31.98 | 0.00% |
| PetMed Express Inc | 13.31 | 0.00% |
| Flamel Technologies SA | 4.65 | 0.00% |
| Acura Pharmaceuticals Inc | 2.30 | 0.00% |
Data is delayed by at least 15 min.